Alaunos Therapeutics Inc

Alaunos Therapeutics, Inc. is a biotechnology company. The Company's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology. ALN1003 is a preclinical, non-incretin, oral candidate targeting metabolic dysfunction beyond weight loss that may address insulin resistance, adipose signaling, liver biology, and body composition. ALN1003 is a preclinical, oral, non-hormonal metabolic therapeutic candidate being evaluated for: obesity-related metabolic dysfunction, MASH-relevant biology, and insulin resistance. The Company is advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. The Company is developing ActRII-Fc ligand traps and complementary biologics. The Company's programs include VLR199, VLR247, VLR258, VLR360 and others.